Author:
Holmes-Hampton Gregory P.,Kumar Vidya P.,Biswas Shukla,Stone Sasha,Sharma Neel K.,Legesse Betre,Vercellino Justin,Guha Chandan,Eichenbaum Gary,Ghosh Sanchita P.
Abstract
AbstractThrombopoietin (TPO) is the primary regulator of platelet generation and a stimulator of multilineage hematopoietic recovery following exposure to total body irradiation (TBI). JNJ‑26366821, a novel PEGylated TPO mimetic peptide, stimulates platelet production without developing neutralizing antibodies or causing any adverse effects. Administration of a single dose of JNJ‑26366821 demonstrated its efficacy as a prophylactic countermeasure in various mouse strains (males CD2F1, C3H/HeN, and male and female C57BL/6J) exposed to Co-60 gamma TBI. A dose dependent survival efficacy of JNJ‑26366821 (− 24 h) was identified in male CD2F1 mice exposed to a supralethal dose of radiation. A single dose of JNJ‑26366821 administered 24, 12, or 2 h pre-radiation resulted in 100% survival from a lethal dose of TBI with a dose reduction factor of 1.36. There was significantly accelerated recovery from radiation-induced peripheral blood neutropenia and thrombocytopenia in animals pre-treated with JNJ‑26366821. The drug also increased bone marrow cellularity and megakaryocytes, accelerated multi-lineage hematopoietic recovery, and alleviated radiation-induced soluble markers of bone marrow aplasia and endothelial damage. These results indicate that JNJ‑26366821 is a promising prophylactic radiation countermeasure for hematopoietic acute radiation syndrome with a broad window for medical management in a radiological or nuclear event.
Publisher
Springer Science and Business Media LLC
Reference46 articles.
1. New drug and biological drug products; evidence needed to demonstrate effectiveness of new drugs when human efficacy studies are not ethical or feasible. Final rule. Fed Regist. 67(105), 37988–37998 (2002).
2. Kelemen, E., Cserhati, I. & Tanos, B. Demonstration and some properties of human thrombopoietin in thrombocythaemic sera. Acta Haematol. 20(6), 350–355 (1958).
3. McDonald, T. P. A comparison of platelet size, latelet count, and platelet 35S incorporation as assays for thrombopoietin. Br. J. Haematol. 34(2), 257–267 (1976).
4. Williams, N. Is thrombopoietin interleukin 6?. Exp. Hematol. 19(7), 714–718 (1991).
5. Wendling, F., Varlet, P., Charon, M. & Tambourin, P. MPLV: A retrovirus complex inducing an acute myeloproliferative leukemic disorder in adult mice. Virology 149(2), 242–246 (1986).